25 mg/0
Sponsors
Ferring Pharmaceuticals A/S, Instituto Bernabeu S.L.
Conditions
Infertility in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycleWomen undergoing ovarian stimulation for oocyte donation.low ovarian reserve according to Bologna criteria and carriers of androgen receptor polymorphism
Phase 3
A randomised, controlled, assessor-blind, parallel groups, multicentre, multinational trial comparing the ovarian response after controlled ovarian stimulation with mixed protocols of follitropin delta (REKOVELLE) and highly purified human menopausal gonadotropin (MENOPUR) in women undergoing an assisted reproductive technology programme
Not yet recruitingCTIS2022-500308-23-00
Target: 115Updated: 2022-11-09
Transdermal testosterone pretreatment in poor responders with androgen receptor polymorphism undergoing ICSI: A Randomized Clinical Investigation.
Not yet recruitingCTIS2024-510596-37-01
Target: 100Updated: 2025-10-06
Phase 4
Evaluation of the efficacy of micronized natural progesterone (Seidigestan®) vs GnRH antagonists (Astarté®) in the prevention of LH surge during controlled ovarian stimulation: a randomized clinical trial.
RecruitingCTIS2023-504188-18-00
Start: 2023-11-08Target: 150Updated: 2023-05-09
Transdermal testosterone pretreatment in poor responders with androgen receptor polymorphism undergoing ICSI: A Randomized Clinical Investigation.
WithdrawnCTIS2024-510596-37-00
Target: 100Updated: 2024-04-29